P. Blower

发表

5‐hydroxytryptamine type‐3 receptor antagonists for chemotherapy‐induced and radiotherapy‐induced nausea and emesis

M. Aapro, P. Blower, 2005, Cancer.

P. Blower, 1993, British journal of rheumatology.

Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat

R. Melarange, C. Gentry, P. Blower, 1994, Digestive Diseases and Sciences.

Nabumetone, in contrast to etodolac, lacks gastrointestinal irritancy in the rat: Assessment by the inflammatory marker, haptoglobin, and blood loss

R. Melarange, C. Gentry, P. Blower, 1995, InflammoPharmacology.

A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ‐free rats

R. Melarange, P. Blower, M. Coates, 1992, Alimentary pharmacology & therapeutics.

5‐HT3‐Receptor Antagonists and the Cytochrome P450 System: Clinical Implications

P. Blower, 2002, Cancer journal.

Antagonism by metoclopramide of some gastrointestinal effects of secretin

P. Blower, M. D. Day, J. Flack, 1978 .

Cardiovascular dopamine receptor stimulation antagonized by metoclopramide

P. Blower, M. D. Day, 1975, The Journal of pharmacy and pharmacology.

The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.

L. Grélot, S. Milano, P. Blower, 1995, The Journal of pharmacology and experimental therapeutics.

Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.

R. Melarange, C. Gentry, P. Blower, 1994, European journal of rheumatology and inflammation.

Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?

M. Aapro, R. de Wit, P. Blower, 2005, Cancer Chemotherapy and Pharmacology.

Drug-drug interactions in oncology: why are they important and can they be minimized?

M. Aapro, R. de Wit, S. Goodin, 2005, Critical reviews in oncology/hematology.

Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.

R. Melarange, P. Blower, R. Spangler, 1994, European journal of rheumatology and inflammation.

Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.

R. Melarange, C. Gentry, P. Blower, 1991, Agents and actions. Supplements.

Granisetron: relating pharmacology to clinical efficacy

P. Blower, 2003, Supportive Care in Cancer.

Are all 5-HT3 receptor antagonists the same?

S. Bingham, P. Andrews, P. Blower, 1992, European journal of cancer.

Comparative sensitivities to antimicrobial agents of Campylobacter pylori and the gastric campylobacter like organism from the ferret.

P. Blower, D. Buckley, L. Jeffries, 1987, Journal of clinical pathology.

The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets

P. Blower, P. T. Davey, E. Boyle, 2005, Journal of Cancer Research and Clinical Oncology.

Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret.

P. Blower, P. T. Davey, E. Boyle, 1994, Pharmacology.

Effect of luminal perfusion rate on duodenal alkalinization in the ratin vivo andin vitro

Julian White, P. Blower, P. Canfield, 1989, Digestive Diseases and Sciences.

Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum.

T. Endo, M. Minami, M. Hirafuji, 1999, Research communications in molecular pathology and pharmacology.

Chemical modulation of 5-HT3 and 5-HT4 receptors affects the release of 5-hydroxytryptamine from the ferret and rat intestine.

T. Endo, M. Minami, M. Hirafuji, 1995, Research communications in molecular pathology and pharmacology.

Cyclophosphamide increases 5-hydroxytryptamine release from the isolated ileum of the rat.

T. Endo, M. Minami, M. Hirafuji, 1997, Research communications in molecular pathology and pharmacology.

Effect of 6-Methoxy-2-Naphthylacetic Acid (6MNA), the Active Metabolite of Nabumetone, on the Glycosaminoglycan Synthesis of Canine Articular Cartilage In Vitro

C. Gentry, P. Blower, R. Spangler, 1995, Clinical drug investigation.

Reply to letter from Russo

P. Blower, 2004, Supportive Care in Cancer.

The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.

P. Blower, 1990, European journal of cancer.

The anti-inflammatory drug nabumetone lacks the gastrointestinal damaging potential of loxoprofen or naproxen.

R. Melarange, C. Gentry, P. Blower, 1991 .

Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?

J. Verweij, M. Aapro, A. Sparreboom, 2002, British Journal of Cancer.

Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA)

R. Melarange, C. Gentry, P. Blower, 1992, Digestive Diseases and Sciences.

A pharmacologic profile of oral granisetron (Kytril tablets).

P. Blower, 1995, Seminars in oncology.

Effect of Granisetron on Performance Status during High-Dose Interferon Therapy

P. Blower, R. Drapkin, Jennifer L. Barolo, 1999, Oncology.